{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:16:10Z","timestamp":1760242570101,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mucopolysaccharidosis III type A (MPS IIIA; Sanfilippo syndrome), a genetic lysosomal disorder causing a deficiency of heparan N-sulfatase (HNS), leads to progressive cognitive decline from an early age. An effective enzyme replacement therapy (ERT) for MPS IIIA requires central nervous system (CNS) biodistribution. Recombinant human heparan N-sulfatase (rhHNS), an investigatory ERT for MPS IIIA, has been formulated for intrathecal (IT) administration since intravenous (IV) administration cannot cross the blood brain barrier (BBB) in sufficient amounts to have a therapeutic effect. In this study, systemic and CNS distribution of rhHNS in cynomolgus monkeys following IV and IT administration was evaluated by quantitation of rhHNS in serum, cerebral spinal fluid (CSF) and various tissues, and positron emission tomography (PET) imaging of live animals. Following IV administration, rhHNS levels were low to non-detectable in the CSF, and systemic clearance was rapid (\u22642 h). With IT administration, rhHNS was observable in CNS tissues in \u22641 h, with varying Tmax (1\u201324 h). Appreciable systemic distribution was observed up to 7 days. This provides evidence that in this animal model, intrathecal administration of rhHNS delivers the replacement enzyme to therapeutically relevant tissues for the treatment of Sanfilippo Syndrome type A. Penetration into grey matter and cortex was 3\u20134 times greater than concentrations in white matter and deeper parenchymal regions, suggesting some limitations of this ERT strategy.<\/jats:p>","DOI":"10.3390\/ijms18122594","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T12:30:16Z","timestamp":1512131416000},"page":"2594","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA"],"prefix":"10.3390","volume":"18","author":[{"given":"Jou-Ku","family":"Chung","sequence":"first","affiliation":[{"name":"Nonclinical Development, Research and Discovery, Shire, 300 Shire Way, Lexington, MA 02421, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9288-6176","authenticated-orcid":false,"given":"Luying","family":"Pan","sequence":"additional","affiliation":[{"name":"Nonclinical Development, Research and Discovery, Shire, 300 Shire Way, Lexington, MA 02421, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Nonclinical Development, Research and Discovery, Shire, 300 Shire Way, Lexington, MA 02421, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Youssef","sequence":"additional","affiliation":[{"name":"KinderPharm\/PKPD Bioscience Inc., 100 Arrandale Blvd #101, Exton, PA 19341, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"McCauley","sequence":"additional","affiliation":[{"name":"Nonclinical Development, Research and Discovery, Shire, 300 Shire Way, Lexington, MA 02421, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"ref_1","unstructured":"Froissart, R., and Maire, I. (2017, June 21). Mucopolysaccharidosis Type 3. Available online: http:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=581."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1172-6-43","article-title":"Cognitive development in patients with mucopolysaccharidosis type iii (sanfilippo syndrome)","volume":"6","author":"Valstar","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpeds.2015.11.079","article-title":"A prospective natural history study of mucopolysaccharidosis type iiia","volume":"170","author":"Shapiro","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13346-011-0043-1","article-title":"Safety evaluation of chronic intrathecal administration of heparan n-sulfatase in juvenile cynomolgus monkeys","volume":"2","author":"Pfeifer","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","article-title":"A phase 1\/2 study of intrathecal heparan-n-sulfatase in patients with mucopolysaccharidosis iiia","volume":"118","author":"Jones","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase i\/ii study of intrathecal idursulfase-it in children with severe mucopolysaccharidosis ii","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"ref_7","unstructured":"Burton, B. (2017, June 21). Orphanet: Mucopolysaccharidosis Type 2, Severe Form. Available online: http:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=217085."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1177\/0192623311409595","article-title":"Safety evaluation of chronic intrathecal administration of idursulfase-it in cynomolgus monkeys","volume":"39","author":"Felice","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Calias, P., Papisov, M., Pan, J., Savioli, N., Belov, V., Huang, Y., Lotterhand, J., Alessandrini, M., Liu, N., and Fischman, A.J. (2012). CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: Implications for neurological outcomes of lysosomal storage disorder. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030341"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Xie, H., Chung, J.K., Mascelli, M.A., and McCauley, T.G. (2015). Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122453"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1203\/01.PDR.0000129661.40499.12","article-title":"Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type iiia mice","volume":"56","author":"Gliddon","year":"2004","journal-title":"Pediatr. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2174\/138920111795542651","article-title":"Mucopolysaccharidosis type iii (sanfilippo syndrome): Emerging treatment strategies","volume":"12","author":"Valstar","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis iiib in adult mice by raav9 trans-blood-brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/humc.2013.208","article-title":"Feasibility and safety of systemic raav9-hnaglu delivery for treating mps iiib: Toxicology, bio-distribution and immunological assessments in primates","volume":"25","author":"Murrey","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1002\/anie.201511539","article-title":"Nondisruptive dissolution of hyperpolarized (129)xe into viscous aqueous and organic liquid crystalline environments","volume":"55","author":"Truxal","year":"2016","journal-title":"Angew. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ymgme.2016.08.002","article-title":"A prospective one-year natural history study of mucopolysaccharidosis types iiia and iiib: Implications for clinical trial design","volume":"119","author":"Truxal","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_17","first-page":"630","article-title":"Brain targeting in mps-iiia","volume":"13","author":"Sorrentino","year":"2016","journal-title":"Pediatr. Endocrinol. Rev. PER"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of gaucher\u2019s disease with n-butyldeoxynojirimycin (ogt 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (zavesca, n-butyldeoxynojirimycin, ogt 918) in type i gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in gaucher\u2019s disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"Bennett","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_22","first-page":"65","article-title":"Enzymatic replacement therapy for hunter disease: Up to 9 years experience with 17 patients","volume":"3","author":"Parini","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Garbuzova-Davis, S., Mirtyl, S., Sallot, S.A., Hernandez-Ontiveros, D.G., Haller, E., and Sanberg, P.R. (2013). Blood-brain barrier impairment in mps iii patients. BMC Neurol., 13.","DOI":"10.1186\/1471-2377-13-174"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.05.009","article-title":"Intrathecal delivery of protein therapeutics to the brain: A critical reassessment","volume":"144","author":"Calias","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1012763026526","article-title":"A fluorimetric enzyme assay for the diagnosis of mps ii (hunter disease)","volume":"24","author":"Voznyi","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/jnc.13533","article-title":"Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type iiia","volume":"137","author":"King","year":"2016","journal-title":"J. Oneurochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/8904_2015_495","article-title":"Continual low-dose infusion of sulfamidase is superior to intermittent high-dose delivery in ameliorating neuropathology in the MPS IIIA mouse brain","volume":"29","author":"Beard","year":"2016","journal-title":"JIMD Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9790-8","article-title":"Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA huntaway dog brain","volume":"38","author":"King","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.expneurol.2015.11.013","article-title":"Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder","volume":"278","author":"King","year":"2016","journal-title":"Exp. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF01799255","article-title":"A fluorimetric enzyme assay for the diagnosis of sanfilippo disease type a (MPS IIIA)","volume":"19","author":"Karpova","year":"1996","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/12\/2594\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:52:15Z","timestamp":1760208735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/12\/2594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["ijms18122594"],"URL":"https:\/\/doi.org\/10.3390\/ijms18122594","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}